Friday, October 5, 2012

Current and Emerging Treatments in the Management of Castration-Resistant Prostate Cancer

Prostate cancer is the second most common cause of death in American men, and a great majority of those men die with CRPC. There are currently four new agents approved in the USA for use in CRPC: cabazitaxel, AA (Abiraterone acetate), sipuleucel-T and denosumab. While the current first line treatments are docetaxel and sipuleucel-T, ongoing and future clinical trials of these new agents, different docetaxel regimens, and emerging and experimental agents aimed at novel targets will lead to changes in the current treatment algorithm outlined in this review.



Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review